The Deeplex® Myc-TB kit, developed by our supplier GenoScreen, is an innovative and integrated culture-free solution, which can provide a diagnosis on a strain’s resistance to 15 anti-TB drugs in less than two days. The assay is based on targeted deep sequencing or Next Generation Sequencing (NGS) and automated data analysis via the Deeplex® Myc-TB secure web application.
Deeplex® Myc-TB detects the TB heteroresistance down to 3%, and also identifies Non-Tuberculous Mycobacteria (NTM), as well as TB lineages and spoligotypes.
This innovative test guides the therapeutic management of TB patients in an effective way, by giving a rapid and extensive prediction of genetic resistance to anti-TB drugs.
The Deeplex® Myc-TB kit includes:
- Deeplex® Master Mix: a single 24-plex PCR mix for culture-free amplification of 18 M. tuberculosis (MTBC) drug resistance-associated gene targets combined with targets for mycobacterial species identification and MTBC strain genotyping.
- An internal control for in-sample quality control.
- A positive control for test validation.
- An activation code to access the Deeplex® Myc-TB web application.
Key aspects:
- 15 anti-tuberculosis drugs screened
- Only 48h from clinical samples to results
- 3% heteroresistance detection sensitivity
- >100 mycobacterial species detectable
- 31 countries have implemented this solution
